Fosamax for Male Osteoporosis: Dosing Protocol, Evidence, and What Clinicians Actually Prescribe

The "Off-Label" Label Is Wrong

Many patients and even some clinicians assume Fosamax is only approved for postmenopausal women. That assumption is outdated. The FDA expanded the alendronate indication to include treatment of osteoporosis in men in 2000, based on a randomized controlled trial published in the New England Journal of Medicine [1].

How the Misconception Persists

Osteoporosis in men receives far less public attention than in women. Roughly 2 million American men have the condition, and another 16.1 million have low bone mass (osteopenia) that may progress [2]. Because the initial 1995 FDA approval of Fosamax targeted postmenopausal osteoporosis, the association stuck. Prescribing databases and insurance formularies sometimes still flag the male indication with prior authorization requirements, reinforcing the belief that it is off-label.

What the FDA Label Actually Says

The current prescribing information for alendronate sodium lists four distinct indications: treatment and prevention of postmenopausal osteoporosis, treatment to increase bone mass in men with osteoporosis, and treatment of glucocorticoid-induced osteoporosis in patients receiving glucocorticoids [3]. Male osteoporosis occupies its own line. No off-label justification is required.

The Key Trial: Orwoll et al. (2000)

The trial that earned the male indication enrolled 241 men with osteoporosis across 18 centers in the United States and seven other countries. Participants received either alendronate 10 mg daily or placebo for two years [1].

Primary Outcome: Lumbar Spine BMD

Men on alendronate gained 7.1% lumbar spine BMD at 24 months compared to 1.8% in the placebo group (P<0.001) [1]. Femoral neck BMD increased by 2.5% versus 0.1%. Total hip BMD rose by 3.1% in the alendronate arm.

Vertebral Fracture Data

The trial recorded an 89% relative risk reduction in new morphometric vertebral fractures among alendronate-treated men compared to placebo (0.8% vs. 7.1%, P=0.02) [1]. The study was not powered for hip fracture endpoints, a limitation shared by most bisphosphonate trials in men due to lower fracture event rates in shorter follow-up periods.

Consistency Across Etiologies

Bone density gains were similar regardless of whether men had primary (idiopathic) osteoporosis or secondary osteoporosis from hypogonadism. This finding is clinically relevant because roughly 30% to 60% of male osteoporosis cases involve an identifiable secondary cause [4].

Dosing Protocol for Men

The approved regimen mirrors the postmenopausal dosing schedule. Two options exist, and both deliver equivalent cumulative exposure over a week [3].

Daily Regimen

Alendronate 10 mg taken every morning on an empty stomach, at least 30 minutes before the first food, beverage (other than plain water), or other oral medication. The tablet must be swallowed whole with 6 to 8 oz of plain water. Patients should not lie down for at least 30 minutes after dosing.

Weekly Regimen

Alendronate 70 mg once weekly. Same administration rules apply. Most clinicians default to the weekly dose because adherence is substantially better. A 2004 analysis in the Journal of Bone and Mineral Research found that patients on weekly bisphosphonate regimens had significantly higher 12-month persistence compared to daily regimens (44.2% vs. 31.7%) [5].

What Not to Do

Calcium or iron supplements, coffee, orange juice, and antacids all reduce alendronate absorption. Bioavailability is already low (approximately 0.7% under fasting conditions), so any food or mineral co-ingestion can drop it close to zero [3]. Patients using proton pump inhibitors should be counseled that some observational data suggest reduced bisphosphonate efficacy, though the clinical significance remains debated [6].

Who Should Receive Alendronate

Not every man with a low T-score needs pharmacotherapy. Guidelines from the Endocrine Society (2012) recommend pharmacologic treatment for men with hip or vertebral fragility fractures, men with T-scores of -2.5 or below at the spine or hip, and men with T-scores between -1.0 and -2.5 when the 10-year FRAX probability exceeds 3% for hip fracture or 20% for major osteoporotic fracture [4].

First-Line Versus Alternative Agents

The Endocrine Society guideline names alendronate, risedronate, zoledronic acid, teriparatide, and denosumab as options for men with osteoporosis [4]. Alendronate and risedronate are typically first-line because of oral convenience, long track records, and generic pricing. "For most men with osteoporosis and no contraindications, an oral bisphosphonate is the appropriate initial therapy," the guideline states [4].

When Alendronate Is Not the Right Choice

Men with active esophageal disorders (stricture, achalasia, inability to remain upright for 30 minutes), severe renal impairment (creatinine clearance <35 mL/min), or hypocalcemia should not receive alendronate [3]. Men at very high fracture risk (multiple vertebral fractures, very low BMD with T-score below -3.0) may benefit from an anabolic agent like teriparatide before transitioning to an antiresorptive.

Monitoring and Follow-Up

Prescribing alendronate without a monitoring plan invites poor outcomes. Baseline and follow-up assessments help confirm the drug is working and catch complications early.

Baseline Labs

Before starting therapy, obtain serum calcium, 25-hydroxyvitamin D, creatinine with eGFR, and a complete metabolic panel. Correct vitamin D deficiency (target 25[OH]D above 30 ng/mL) and ensure daily calcium intake of 1,000 to 1,200 mg from diet plus supplements before initiating the bisphosphonate [4].

DXA Timing

Repeat DXA at the hip and lumbar spine after 1 to 2 years of treatment. A stable or rising BMD confirms response. A decline of more than 3% to 5% at any site warrants evaluation for nonadherence, malabsorption, or a secondary cause of bone loss that was not identified at baseline [7].

Bone Turnover Markers

Serum C-telopeptide (CTX) or procollagen type I N-terminal propeptide (P1NP) can confirm pharmacologic response within 3 to 6 months, faster than DXA. A CTX reduction of 30% or more from baseline generally indicates adequate suppression of bone resorption [7]. Not every practice checks markers routinely, but they are useful when adherence is uncertain or BMD changes are equivocal.

Duration of Therapy and Drug Holidays

Bisphosphonates bind to hydroxyapatite in bone and persist for years after discontinuation. This skeletal half-life raises both an advantage (residual benefit) and a concern (cumulative exposure and rare adverse events).

The FLEX Trial Framework

The landmark Fracture Intervention Trial Long-Term Extension (FLEX) studied women, not men, but its findings inform practice across sexes. After 5 years of alendronate, women randomized to placebo maintained stable hip BMD over the next 5 years, while vertebral BMD declined modestly [8]. The study suggested that a drug holiday after 5 years is reasonable for patients not at highest risk.

Applying Drug Holidays to Men

No equivalent randomized trial exists in men. In practice, most guidelines recommend reassessing after 3 to 5 years. Men who started alendronate for moderate risk (T-score between -2.5 and -1.5 on FRAX-based criteria) and who have gained BMD can often pause for 2 to 3 years. Men with prevalent vertebral fractures or T-scores that remain below -2.5 may benefit from continued therapy or a switch to a different agent [4].

Monitoring During a Drug Holiday

After discontinuation, repeat DXA every 2 years. If BMD drops by more than 3% to 5%, or if a new fracture occurs, restart therapy. Bone turnover markers rising above the premenopausal reference range can signal that the bisphosphonate's residual effect has waned.

Safety Profile in Men

Alendronate's adverse event profile in men is consistent with data from the larger postmenopausal trials. The drug has been on the market since 1995, and the safety database spans millions of patient-years.

Gastrointestinal Effects

Upper GI complaints (dyspepsia, nausea, esophageal irritation) are the most common reason men discontinue oral bisphosphonates. Proper administration technique (upright posture, adequate water, empty stomach) reduces these events significantly [3]. In the Orwoll trial, GI adverse events were similar between alendronate and placebo groups [1].

Osteonecrosis of the Jaw (ONJ)

ONJ associated with oral bisphosphonates is rare. A 2015 systematic review estimated the incidence at 0.001% to 0.01% in the oral bisphosphonate population, compared to approximately 1% to 15% in patients receiving high-dose intravenous bisphosphonates for cancer [9]. The American Association of Oral and Maxillofacial Surgeons recommends a dental examination before starting therapy but does not recommend delaying treatment for dental clearance [9].

Atypical Femoral Fractures (AFF)

AFFs are subtrochanteric or diaphyseal femur fractures associated with prolonged bisphosphonate use, typically beyond 5 years. A large Kaiser Permanente cohort study (N=196,129) found that AFF risk increased with duration of bisphosphonate use but declined rapidly after discontinuation [10]. The absolute risk remains low: approximately 1.74 per 10,000 patient-years after 5 or more years of use [10]. Drug holidays after 3 to 5 years are partly intended to mitigate this risk.

Cost and Access

Generic alendronate is one of the least expensive osteoporosis medications available. Brand-name Fosamax is largely unnecessary from a clinical standpoint since generics have been available since 2008.

Pricing

A 30-day supply of generic alendronate 70 mg (four tablets) costs between $4 and $15 at most large chain pharmacies. GoodRx and similar discount programs frequently list it below $10 without insurance [11]. By contrast, monthly denosumab (Prolia) injections cost approximately $1,600 to $2,000 per dose at list price, and teriparatide (Forteo) runs roughly $3,600 per month.

Insurance Coverage

Because alendronate is generic and FDA-approved for male osteoporosis, coverage is rarely an issue. Medicare Part D, Medicaid, and commercial plans typically place it on Tier 1 or Tier 2 formularies with minimal or zero copay. Prior authorization is uncommon, though some plans require documentation of a DXA scan confirming osteoporosis.

How Alendronate Compares to Other Male Osteoporosis Treatments

Men have fewer approved pharmacologic options than postmenopausal women. Direct head-to-head trials comparing agents in men are scarce.

Alendronate vs. Zoledronic Acid

Zoledronic acid (Reclast) is given as a once-yearly IV infusion (5 mg). It eliminates adherence concerns entirely. The HORIZON trial in men showed a 67% relative risk reduction in morphometric vertebral fractures [12]. For men who cannot tolerate oral bisphosphonates or who have poor adherence, zoledronic acid is a strong alternative. The trade-off: it requires an infusion visit, and acute-phase reactions (fever, myalgia) occur in roughly 30% of first-time recipients.

Alendronate vs. Denosumab

Denosumab (Prolia) is a RANK ligand inhibitor approved for male osteoporosis. The ADAMO trial (N=242) showed a 5.7% lumbar spine BMD increase at 12 months versus 0.9% placebo in men [13]. Denosumab does not require fasting, is given as a subcutaneous injection every 6 months, and works in men with renal impairment. The major concern: discontinuation triggers rapid bone loss and a rebound in vertebral fractures. A bisphosphonate must follow denosumab cessation.

Alendronate vs. Teriparatide

Teriparatide (Forteo) is a parathyroid hormone analog that builds new bone rather than slowing resorption. It is reserved for men at very high fracture risk. Daily subcutaneous injections for up to 2 years produce large BMD gains (approximately 13% lumbar spine in men), after which patients transition to a bisphosphonate to maintain gains [14]. Cost and injection burden make it a second-line or sequential option.

Clinical Workflow: Starting Alendronate in a Male Patient

A practical checklist for clinicians initiating alendronate in men with confirmed osteoporosis:

1. Confirm T-score of -2.5 or below, or FRAX-qualifying intermediate risk, via DXA.
2. Evaluate for secondary causes: check testosterone, TSH, serum protein electrophoresis, 24-hour urine calcium, and celiac serologies if clinically indicated.
3. Correct calcium and vitamin D deficiency before starting.
4. Prescribe alendronate 70 mg weekly (preferred for adherence) or 10 mg daily.
5. Counsel on administration: empty stomach, plain water only, upright posture for 30 minutes.
6. Order baseline CTX or P1NP (optional but useful for tracking response).
7. Schedule dental evaluation if invasive dental procedures are anticipated.
8. Recheck bone turnover markers at 3 to 6 months if obtained at baseline.
9. Repeat DXA at 2 years.
10. Reassess at 3 to 5 years for drug holiday eligibility.

This sequence aligns with the Endocrine Society 2012 guideline recommendations for pharmacologic management of osteoporosis in men [4].